- Breaking News Related to Macular Degeneration, Cataract, Glaucoma, Corneal Disease and Other Eye Conditions - http://eyedocnews.com -

Update on Avastin vs. Lucentis: CMS Ups the Ante

Posted By Irv Arons On October 8, 2009 @ 10:19 am In Consultant Articles,Industry News,Macular Degeneration,Retina | Comments Disabled

TheĀ  Centers for Medicare and Medicaid Services (CMS) have decided to change the reimbursement rate for small Avastin doses, as used in the treatment of wet age-related macular degeneration, reducing the reimbursement from about $25-30 per dose, to about $7.20, causing an increased cost to physicians that routinely use the compounded Avastin in ophthalmology.

On the other hand, the roughly $2000 cost per dose for Lucentis is fully reimbursed.

This change occurred this week and, as you can imagine, there has been much written and discussed about this change.

I have reproduced two articles, from the NY Times and the Wall Street Journal, as well as a report on discussions about this occurring at the Retina Congress 2009, on my online Journal.

For the complete story please check out my writeup [1].


Article printed from Breaking News Related to Macular Degeneration, Cataract, Glaucoma, Corneal Disease and Other Eye Conditions: http://eyedocnews.com

URL to article: http://eyedocnews.com/002302-update-on-avastin-vs-lucentis-cms-ups-the-ante/

URLs in this post:

[1] check out my writeup: http://tinyurl.com/Update26CMS

Copyright © 2008 Eye Doc Talk. All rights reserved.